Core Viewpoint - The company, BaiOsaite (688796.SH), has announced its initial public offering (IPO) on the Sci-Tech Innovation Board, planning to issue 47.5 million shares, which represents 10.63% of the total share capital post-issue [1] Group 1: Company Overview - Established in 2009, the company operates as a preclinical Contract Research Organization (CRO) and biotechnology firm, focusing on gene editing technology to provide innovative model animals and preclinical drug development services [1] - The company has developed the RenMice platform, which includes various series of fully human antibodies/TCR mice, aimed at large-scale drug discovery targeting over a thousand potential drug targets [1] - The company has evolved into a comprehensive entity with four technical platforms: gene-edited model animal preparation, innovative model animal breeding and supply, preclinical pharmacology and efficacy evaluation, and antibody drug discovery [1] Group 2: Business Performance - As of the reporting period, the company has completed approximately 5,300 customized gene editing projects and developed over 4,300 types of gene-edited animals and cell line models [2] - The company’s innovative model animals and cell products include humanized mouse models targeting immune checkpoints and cytokines, severe immunodeficient mice, various spontaneous disease models, and human-derived cell lines, covering areas such as tumors, autoimmune diseases, metabolism, and neurology [2] - The company's main business revenues for the reporting periods were 533 million yuan, 716 million yuan, 980 million yuan, and 621 million yuan, with a compound annual growth rate of 35.56% from 2022 to 2024 [2] Group 3: Fundraising and Investment Plans - The funds raised from the IPO, after deducting issuance costs, will be allocated to several projects in order of priority: early drug development service platform construction, antibody drug research and evaluation, preclinical research projects, and supplementing working capital, with a total investment amount of 1.185 billion yuan [3]
临床前CRO以及生物技术企业百奥赛图拟于科创板IPO上市